NeurologyLive® Friday 5 — May 31, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Understanding Silent Progression in Multiple Sclerosis: Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center discussed the early-onset progression of multiple sclerosis and emphasized the need for targeted therapies in this patient population. [WATCH TIME: 6 minutes]

2: Researching Dravet Syndrome Biomarkers to Advance Treatment: Christos Papadelis, PhD

The director of research in the Jane and John Justin Neurosciences Center at Cook Children's Health Care System talked about ongoing research on biomarkers to enhance treatment and improve cognitive outcomes. [WATCH TIME: 6 minutes]

3: NeurologyLive® Clinician of the Month Spotlight: Merit Cudkowicz, MD, MSc

As part of our monthly clinician spotlight, NeurologyLive® highlighted neuromuscular disorder expert Merit Cudkowicz, MD, MSc, chair of neurology at Massachusetts General Hospital.

4: NeuroVoices: Michael Levy, MD, PhD, on Comparing Patient Outcomes of Inebilizumab and Rituximab in NMOSD

In this week's NeuroVocies Q&A, the associate professor of neurology at Harvard Medical School talked about results from a recent study that evaluated the efficacy of inebilizumab versus rituximab in treating NMOSD.

5: Utilization of APOE4 Genotype in Management of Alzheimer’s Disease

In episode 8 of a Peer Exchange video series, medical experts discussed the application of ApoE gene polymorphism and copy number data in managing Alzheimer disease (AD), highlighting its relevance for individuals with a family history of AD, and symptomatic patients.